Skip to main content

Table 1 Prevalence of features of metabolic syndrome at baseline in patients assigned to placebo in the FIELD study (points of difference in criteria are shown in bold)

From: Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the field randomised trial

Feature of metabolic syndrome

Men

Women

All patients

 

(n = 3067)

(n = 1833)

(n = 4900)

ATPIII criteria (any 3)

   

Diabetes or impaired fasting glucose

100

100

100

High waist measurement (M > 102 cm, F > 88 cm)

54.5

80.6

64.3

Hypertension history or BP ≥ 130/85 mmHg

82.2

85.8

83.6

High triglycerides (≥ 1.7 mmol/L)

50.0

54.1

51.5

Low HDL cholesterol (M < 1.03 mmol/L, F < 1.29 mmol/L)

54.8

66.2

59.1

Metabolic syndrome according to ATPIII

78.3

90.3

82.8

IDF criteria (waist + any 2)

   

Diabetes or impaired fasting glucose

100

100

100

High waist measurement (M ≥ 94 cm, F ≥ 80 cm)

83.9

95.0

88.0

Hypertension history or BP ≥ 130/85 mmHg

82.2

85.8

83.6

High triglycerides (≥ 1.7 mmol/L)

50.0

54.1

51.5

Low HDL cholesterol (M < 1.03 mmol/L, F < 1.29 mmol/L)

54.8

66.2

59.1

Metabolic syndrome according to IDF

80.5

92.5

85.0

Harmonized criteria (any 3)

   

Diabetes or impaired fasting glucose

100

100

100

High waist measurement (M ≥ 94 cm, F ≥ 80 cm)

83.9

95.0

88.0

Hypertension history or BP ≥ 130/85 mmHg

82.2

85.8

83.6

High triglycerides (≥ 1.7 mmol/L)

50.0

54.1

51.5

Low HDL cholesterol (M < 1.03 mmol/L, F < 1.29 mmol/L)

54.8

66.2

59.1

Metabolic syndrome according to harmonized definition

87.6

94.7

90.3

WHO criteria (diabetes + any 2)

   

Diabetes or impaired fasting glucose

100

100

100

High waist-hip ratio (M > 0.9, F > 0.85) or BMI > 30

88.5

80.5

85.5

Hypertension history or blood pressure ≥ 140/90 mmHg

68.5

73.3

70.3

High triglycerides (≥ 1.7 mmol/L) and/or low HDL-c (M < 0.9 mmol/L, F < 1.0 mmol/L)

58.9

59.0

58.9

Microalbuminuria (urine albumin/creatinine ≥ 3.4 mg/mmol)

23.6

20.8

22.6

Metabolic syndrome according to WHO

82.6

80.7

81.9

  1. * IDF criteria for hypertension, high triglyceride, and low HDL-c are the same as those for ATPIII.
  2. † Harmonized criteria are the same as for IDF except metabolic syndrome does not require high waist measurement.
  3. ‡ Ethnic and sex-specific cut-offs for waist circumference define high risk in the harmonized definition. This analysis, for a population mainly of European origin, used the "Caucasian" waist cut-off.
  4. FIELD, Fenofibrate Intervention and Event Lowering in Diabetes; ATPIII, Adult Treatment Panel III; M, male; F, female; BP, blood pressure; IDF, International Diabetes Federation; WHO, World Health Organization; HDL-c, high-density lipoprotein cholesterol